The market for advanced cell models is booming and expected to grow from $1.42 billion in 2022 to $5.29 billion by 2032. This surge is driven by the unique properties of advanced cell models: They can ...

We unpack the full scope of the U.S. budget cuts, from canceled clinical trials and stalled drug approvals to mass layoffs ...

Explore the latest NSCLC new treatments in development, including candidates aimed at tackling hard-to-treat, late-stage lung ...

Discover six hemophilia companies developing new treatments for the genetic bleeding disorder, from gene therapies to RNAi ...

The antibody discovery landscape is at a turning point. As the demand for more effective and targeted therapeutics grows to tackle challenging targets, traditional methods—focused on binding rather ...